Sopharma AD (WSE:SPH)

Market Cap	2.40B
Revenue (ttm)	4.86B
Net Income (ttm)	189.23M
Shares Out	n/a
EPS (ttm)	1.08
PE Ratio	12.66
Forward PE	n/a
Dividend	0.36 (2.70%)
Ex-Dividend Date	Nov 7, 2024

Volume	5
Average Volume	641
Open	13.45
Previous Close	14.90
Day's Range	13.45 - 13.45
52-Week Range	11.40 - 15.60
Beta	-0.23
RSI	45.18
Earnings Date	May 30, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1933
• Employees: 5,599
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: SPH

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.

Financial numbers in BGN